Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
Precision Prevention: Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
PRIMARY OBJECTIVES:
I. To assess patient interest and emotional responses toward EERA and return of results.
II. To assess provider attitudes toward EERA integration into clinical workflows.
OUTLINE: This is an observational study. Participants are assigned to 1 of 3 aims.
AIM I: Average and high risk breast cancer participants and early onset breast cancer patients complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' and patients' medical records are reviewed.
AIM II: COH providers complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.
AIM III: Average and high risk breast cancer participants complete a baseline survey over 15-25 minutes and wear Fresh Air Clip wristbands for 1 week. Participants then complete a follow up survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' medical records are reviewed.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Contacts et emplacements
Lieux d'étude
-
-
California
-
Duarte, California, États-Unis, 91010
- Recrutement
- City of Hope Medical Center
-
Chercheur principal:
- Stacy W. Gray
-
Contact:
- Stacy W. Gray
- Numéro de téléphone: 626-218-4768
- E-mail: stagray@coh.org
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
AIM 1 INCLUSION CRITERIA:
ONE of the following:
- Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no Pathogenic/Likely Pathogenic [P/LP] in breast cancer related genes) OR high risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model or gene mutation carrier, P/LP carrier in breast cancer related genes including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53) OR early onset breast cancer (defined by a breast cancer diagnosis in a patient younger than 50 years of age)
- Age: ≥ 18 years
- Speak English or Spanish
- Sex: female
Willingness to:
- Participate in study activities
- Permit medical record/ clinical laboratory result review
AIM 2 INCLUSION CRITERIA
- Practice at COH (i.e., genetic counselors, geneticists, oncologists, nurse practitioners)
Willingness to:
- Participate in study activities
AIM 3 INCLUSION CRITERIA:
- Provide written consent
ONE of the following:
- Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no P/LP in breast cancer related genes) OR High risk: empirical risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model and no P/LP in breast cancer related genes) OR High Risk: gene carrier (defined by P/LP carrier in breast cancer related genes, including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53)
- Age: ≥ 18 years
- Speak English or Spanish
- Sex: female
Willingness to:
- Wear the wristband for 1 week
- Participate in study activities
- Permit medical record/ clinical laboratory result review
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Observational Aim I
Average and high risk breast cancer participants and early onset breast cancer patients complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.
Participants' and patients' medical records are reviewed.
|
Étude non interventionnelle
Autres noms:
|
|
Observational Aim II
COH providers complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.
|
Étude non interventionnelle
Autres noms:
|
|
Observational Aim III
Average and high risk breast cancer participants complete a baseline survey over 15-25 minutes and wear Fresh Air Clip wristbands for 1 week.
Participants then complete a follow up survey over 15-25 minutes and may attend an interview over 30-45 minutes.
Participants' medical records are reviewed.
|
Étude non interventionnelle
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient survey responses on perceived utility
Délai: Up to one year
|
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using analysis of covariance (ANCOVA).
Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores.
ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors.
Interview sessions will be audio-recorded and transcribed verbatim.
|
Up to one year
|
|
Patient survey responses on willingness to engage
Délai: Up to one year
|
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA.
Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores.
ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors.
Interview sessions will be audio-recorded and transcribed verbatim.
|
Up to one year
|
|
Patient survey responses on preferences for receiving EERA results
Délai: Up to one year
|
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA.
Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores.
ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors.
Interview sessions will be audio-recorded and transcribed verbatim.
|
Up to one year
|
|
Provider survey responses on perceived utility
Délai: Up to one year
|
Descriptive analysis will be used to examine all quantitative variables.
|
Up to one year
|
|
Provider survey responses on feasibility
Délai: Up to one year
|
Descriptive analysis will be used to examine all quantitative variables.
|
Up to one year
|
|
Provider survey responses on preferences for EERA disclosures into workflows
Délai: Up to one year
|
Descriptive analysis will be used to examine all quantitative variables.
|
Up to one year
|
|
Proportion of participants who wear the work wristband for a total of 1 week
Délai: Up to one year
|
Feasibility will be defined as the proportion of participants who wear the work wristband for a total of 1 week.
The feasibility rate will be summarized descriptively using point estimates and 95% confidence intervals.
|
Up to one year
|
|
Chemical exposure measured by Fresh Air Clip wristband
Délai: Up to one year
|
Acceptability will be measured in the follow-up survey using the question: "Overall, how acceptable did you find wearing the 'Fresh Air clip' wristband to measure chemical exposures in your daily life?"
Participants who respond "No opinion," "Acceptable," or "Completely acceptable" will be categorized as finding the wristband acceptable.
The acceptability rate will be summarized descriptively using point estimates and 95% confidence intervals.
|
Up to one year
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Stacy W Gray, City of Hope Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 260159 (Autre identifiant: City of Hope Medical Center)
- P30CA033572 (Subvention/contrat des NIH des États-Unis)
- NCI-2026-04271 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .